Investor Relations

About
Pipeline
- Overview
- SNS-301
- SNS-401
- Vista
- Presentations
Platform
Our Leadership
Careers
Investors and Media

Contact

Investor Relations

About
Pipeline
- Overview
- SNS-301
- SNS-401
- Vista
- Presentations
Platform
Our Leadership
Careers
Investors and Media

Contact Us

Investor Contact:

Julie Seidel | Courtney Turiano
Stern Investor Relations, Inc.
ir@senseibio.com

Name

Email

Subject

Comments

Leave this field blank

Investor Tools

Email Alerts
Investor FAQs
RSS Feeds
Contact Us

About

We are a biopharmaceutical company engaged in the discovery, development and delivery of next generation immunotherapies with an initial focus on treatments for cancer. We have developed two unique approaches – our ImmunoPhage™ platform and our monoclonal antibody and nanobody platform. Our proprietary ImmunoPhage™️ platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. Using the ImmunoPhage platform, we are developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens. Our monoclonal antibody and nanobody platform is comprised of unique human monoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment. Together, these platforms are designed to create a new class of personalized immuno-oncology medicines.

Contact

Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850

Phone No

+1.240.243.8000

Boston R&D Location
451 D Street, Suite 710
Boston, MA 02210

Email

info@senseibio.com

Legal

Privacy Policy

Social Links

Go to Top